Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HLX48 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on HLX48, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and MET (Jul 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HLX48 | HLX-48|HLX 48 | EGFR Antibody 80 MET Antibody 41 | Limited information is currently available on HLX48, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and MET (Jul 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07473726 | Phase I | HLX48 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |